ZyVersa Therapeutics is a clinical stage biopharmaceutical company developing drugs for chronic renal and inflammatory diseases with high unmet medical needs. The company has two proprietary drug development platforms discovered by University of Miami research scientists: VAR 200 (2-hydroxypropyl-beta-cyclodextrin), an injectable drug in clinical development for renal diseases with focal segmental glomerulosclerosis (FSGS) as lead indication, and IC 100, a humanized monoclonal antibody in preclinical development targeting inflammasome ASC for inflammatory conditions, with cardiometabolic conditions associated with obesity as lead indication.
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001493152-26-014271 | EDGAR | 55K words |
| 2025-03-27 | 2024-12-31 | 0001641172-25-000862 | EDGAR | 96K words |
| 2024-03-25 | 2023-12-31 | 0001493152-24-011073 | EDGAR | 110K words |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010259 | EDGAR | 125K words |
| 2022-04-15 | 2021-12-31 | 0001213900-22-019895 | EDGAR | 43K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-19 | 2025-09-30 | 0001493152-25-024263 | EDGAR | 20K words |
| 2025-08-13 | 2025-06-30 | 0001641172-25-023342 | EDGAR | 19K words |
| 2025-05-12 | 2025-03-31 | 0001641172-25-009724 | EDGAR | 15K words |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045351 | EDGAR | 19K words |
| 2024-08-09 | 2024-06-30 | 0001493152-24-031002 | EDGAR | 17K words |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019517 | EDGAR | 15K words |
| 2023-11-14 | 2023-09-30 | 0001493152-23-041185 | EDGAR | 23K words |
| 2023-08-21 | 2023-06-30 | 0001493152-23-029603 | EDGAR | 22K words |
| 2023-05-12 | 2023-03-31 | 0001493152-23-016480 | EDGAR | 15K words |
| 2022-11-14 | 2022-09-30 | 0001213900-22-072377 | EDGAR | 19K words |
| 2022-08-15 | 2022-06-30 | 0001213900-22-048196 | EDGAR | 17K words |
| 2022-05-13 | 2022-03-31 | 0001213900-22-026061 | EDGAR | 16K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-16 | 0001493152-26-033565 | EDGAR | 0K words |
| 2026-03-05 | 0001493152-26-008994 | EDGAR | 16K words |
| 2025-12-03 | 0001493152-25-025966 | EDGAR | 1K words |
| 2025-11-19 | 0001493152-25-024273 | EDGAR | 1K words |
| 2025-10-15 | 0001493152-25-018156 | EDGAR | 1K words |
| 2025-09-18 | 0001493152-25-013968 | EDGAR | 1K words |
| 2025-07-28 | 0001641172-25-021100 | EDGAR | 1K words |
| 2025-07-16 | 0001641172-25-019856 | EDGAR | 1K words |
| 2025-07-09 | 0001641172-25-018403 | EDGAR | 10K words |
| 2025-06-25 | 0001641172-25-016388 | EDGAR | 1K words |
106 total filings indexed. 79 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001859007 |
| Ticker | ZVSA |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ZVSA (~200 tokens, structured JSON with cryptographic provenance)